Parallel Session 2

London Declaration on Neglected Tropical Diseases – Quo vadis?

Together with representatives from the Pediatric Praziquantel Consortium, PDE4NPD, and MMV-PDP

Neglected Tropical Diseases (NTDs) are a group of infectious diseases affecting an estimated 1.4 billion people worldwide. Their combined disease burden makes a huge economic, social, and health impact, especially in low-income countries in developing regions of Africa, Asia, and Latin-America. Since 2012, many product development partnerships (PDPs), funders, academic institutes, NGOs, pharmaceutical companies, and governments have joined forces under the umbrella of the London Declaration on NTDs and the WHO NTD Roadmap. The goal is to support, initiate, and implement a multitude of NTD programs, from research through to development and access.

Funders such as the Bill and Melinda Gates Foundation, EDCTP, the Dutch PDP Fund, and the GHIT Fund are providing the necessary support to allow promising new health solutions for NTDs. Pharmaceutical companies and PDPs have a number of potential diagnostics, drugs, and vaccines in the pipeline. The global infectious disease communities, including the Dutch, are providing necessary pathophysiological, epidemiological, and clinical knowledge around NTDs. It is clear that great progress has been made. But the question lingers: have we together generated sufficient momentum, knowledge, and resources to overcome the global impact of NTDs in the next decade?

During this parallel session, different (inter)national experts from academia, industry, the government, and NGOs will share their experiences and views on how the field of Neglected Tropical Diseases R&D has progressed since 2012. They will provide a glimpse of what is still required to move forward. After the presentations, the audience will have ample opportunity to share and discuss with the experts their experiences, needs, and outlook for the future.


  • Cees de Joncheere (Chair), former Director of the Essential Medicines and Health Products Department, WHO
  • Jutta Reinhard-Rupp, Head of Translational Innovation Platform Global Health, Merck
  • Wieneke Vullings, ‎Deputy Head, Health and Aids division Dutch Ministry of Foreign Affairs
  • Maria Yazdanbakhsh, Professor of Cellular Immunology of Parasitic Infections, Leiden University Medical Center
  • Ed Zijlstra, Head of Mycetoma programme, DNDi

back to program